Bayer launches Bayer Co.Lab Adventure Platform In China To Accelerate Access To Global Investment Network Enhancing Biotech Innovation
09 September 2025, Germany: Bayer today announced the launch of Bayer Co.Lab AdVenture, a new platform for its Bayer Co.Lab global life sciences incubator network, which aims to connect venture capital partners globally. Bayer Co.Lab AdVenture bridges tenants of high-potential biotech startups with leading venture capital firms, accelerating access to global financing and investment networks, thereby advancing the translation of early-stage ideas into impactful global solutions.
This significant advancement was introduced on the first anniversary of Bayer Co.Lab Shanghai, which also welcomed two additional Chinese biotech startups into its vibrant community. These milestones signify a pivotal moment in Bayer’s open innovation strategy and reinforce its commitment to deeply rooting in countries with a strong innovation footprint, while fostering global connections.
“Collaboration is essential to driving pharmaceutical innovation,” said Juergen Eckhardt, M.D., Head of Business Development and Licensing at Bayer’s Pharmaceuticals Division. “With the introduction of Bayer Co.Lab AdVenture, we are partnering with leading venture capital firms to empower biotech start-ups by providing access to global financing and investment networks that accelerates their growth. We will continue to deepen collaboration with innovators and partners, driving transformative innovations to address global health challenges and improve outcomes for patients worldwide.”
The inaugural partners of Bayer Co.Lab AdVenture include Shanghai Industrial Investment Capital (SIIC), Legend Capital, IDG Capital, and Bayland Capital. Drawing on deep investment expertise and strong local networks, these firms will support Bayer Co.Lab resident startups with strategic advice and curated investment opportunities.
At the anniversary event, Bayer Co.Lab Shanghai welcomed OTR Therapeutics and Nutshell Therapeutics as new start-up resident whose research & development (R&D) directions closely align with Bayer’s global strategic priorities, reflecting a shared commitment to innovative, high-potential treatment modalities that address high unmet medical needs.
Also Read: DialogueNEXT India: 60 Years of Borlaug’s Legacy, Global Leaders Convene to Confront Hunger
📢 If You’re in Agriculture, Make Sure the Right People Hear Your Story.
From product launches to strategic announcements, Global Agriculture offers unmatched visibility across international agri-business markets. Connect with us at pr@global-agriculture.com to explore editorial and advertising opportunities that reach the right audience, worldwide.
